PREVAIL: Urothelial Carcinoma Registry
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

PREVAIL: Urothelial Carcinoma Registry

Sponsor: AstraZeneca

Protocol D419BR00008. A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma.